A purinerg jelátviteli rendszer szerepe depressziós kórképekben

Translated title of the contribution: The role of purinergic signaling in depressive disorders

B. Sperlágh, Cecilia Csolle, Romeo D. Ando, Flora Goloncser, A. Kittel, M. Baranyi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The purinergic signaling system consists of transporters, enzymes and receptors responsible for the synthesis, release, action and extracellular inactivation of adenosine 5'-triphosphate (ATP) and its extracellular breakdown product adenosine. The actions of ATP are mediated ionotropic P2X and metabotropic P2Y receptor subfamilies, whilst the actions of adenosine are mediated by P1 adenosine receptors. Purinergic signaling pathways are widely expressed in the central nervous system (CNS) and participate in its normal and pathological functions. Among P2X receptors, the P2X7 receptor (P2rx7) has received considerable interest in both basic and clinical neuropsychiatric research because of its profound effects in animal CNS pathology and its potential involvement as a susceptibility gene in mood disorders. Although genetic findings were not always consistently replicated, several studies demonstrated that single nucleotide polymorphisms (SNPs) in the human P2X7 gene (P2RX7) show significant association with major depressive disorder and bipolar disorder. Animal studies revealed that the genetic knock-down or pharmacological antagonism leads to reduced depressive-like behavior, attenuated response in mania-model and alterations in stress reactivity. A potential mechanism of P2rx7 activation on mood related behavior is increased glutamate release, activation of extrasynaptic NMDA receptors and subsequent enduring changes in neuroplasticity. In addition, dysregulation of monoaminergic transmission and HPA axis reactivity could also contribute to the observed changes in behavior. Besides P2rx7, the inhibition of adenosine A1 and A 2A receptors also mediate antidepressant-like effects in animal experiments. In conclusion, despite contradictions between existing data, these findings point to the therapeutic potential of the purinergic signaling system in mood disorders.

Original languageHungarian
Pages (from-to)231-238
Number of pages8
JournalNeuropsychopharmacologia Hungarica
Volume14
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Depressive Disorder
Mood Disorders
Bipolar Disorder
Adenosine
Central Nervous System
Adenosine Triphosphate
Purinergic P2X7 Receptors
Adenosine A2A Receptors
Neuronal Plasticity
Purinergic P1 Receptors
Major Depressive Disorder
N-Methyl-D-Aspartate Receptors
Antidepressive Agents
Genes
Single Nucleotide Polymorphism
Glutamic Acid
Pharmacology
Pathology
Enzymes
Research

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

A purinerg jelátviteli rendszer szerepe depressziós kórképekben. / Sperlágh, B.; Csolle, Cecilia; Ando, Romeo D.; Goloncser, Flora; Kittel, A.; Baranyi, M.

In: Neuropsychopharmacologia Hungarica, Vol. 14, No. 4, 2012, p. 231-238.

Research output: Contribution to journalArticle

Sperlágh, B. ; Csolle, Cecilia ; Ando, Romeo D. ; Goloncser, Flora ; Kittel, A. ; Baranyi, M. / A purinerg jelátviteli rendszer szerepe depressziós kórképekben. In: Neuropsychopharmacologia Hungarica. 2012 ; Vol. 14, No. 4. pp. 231-238.
@article{12941dc350a340049d523ede9793a070,
title = "A purinerg jel{\'a}tviteli rendszer szerepe depresszi{\'o}s k{\'o}rk{\'e}pekben",
abstract = "The purinergic signaling system consists of transporters, enzymes and receptors responsible for the synthesis, release, action and extracellular inactivation of adenosine 5'-triphosphate (ATP) and its extracellular breakdown product adenosine. The actions of ATP are mediated ionotropic P2X and metabotropic P2Y receptor subfamilies, whilst the actions of adenosine are mediated by P1 adenosine receptors. Purinergic signaling pathways are widely expressed in the central nervous system (CNS) and participate in its normal and pathological functions. Among P2X receptors, the P2X7 receptor (P2rx7) has received considerable interest in both basic and clinical neuropsychiatric research because of its profound effects in animal CNS pathology and its potential involvement as a susceptibility gene in mood disorders. Although genetic findings were not always consistently replicated, several studies demonstrated that single nucleotide polymorphisms (SNPs) in the human P2X7 gene (P2RX7) show significant association with major depressive disorder and bipolar disorder. Animal studies revealed that the genetic knock-down or pharmacological antagonism leads to reduced depressive-like behavior, attenuated response in mania-model and alterations in stress reactivity. A potential mechanism of P2rx7 activation on mood related behavior is increased glutamate release, activation of extrasynaptic NMDA receptors and subsequent enduring changes in neuroplasticity. In addition, dysregulation of monoaminergic transmission and HPA axis reactivity could also contribute to the observed changes in behavior. Besides P2rx7, the inhibition of adenosine A1 and A 2A receptors also mediate antidepressant-like effects in animal experiments. In conclusion, despite contradictions between existing data, these findings point to the therapeutic potential of the purinergic signaling system in mood disorders.",
keywords = "Adenosine, ATP, Bipolar disorder, Depressive disorder, P2X7 receptor, Purinergic receptors",
author = "B. Sperl{\'a}gh and Cecilia Csolle and Ando, {Romeo D.} and Flora Goloncser and A. Kittel and M. Baranyi",
year = "2012",
doi = "10.5706/nph201212003",
language = "Hungarian",
volume = "14",
pages = "231--238",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - A purinerg jelátviteli rendszer szerepe depressziós kórképekben

AU - Sperlágh, B.

AU - Csolle, Cecilia

AU - Ando, Romeo D.

AU - Goloncser, Flora

AU - Kittel, A.

AU - Baranyi, M.

PY - 2012

Y1 - 2012

N2 - The purinergic signaling system consists of transporters, enzymes and receptors responsible for the synthesis, release, action and extracellular inactivation of adenosine 5'-triphosphate (ATP) and its extracellular breakdown product adenosine. The actions of ATP are mediated ionotropic P2X and metabotropic P2Y receptor subfamilies, whilst the actions of adenosine are mediated by P1 adenosine receptors. Purinergic signaling pathways are widely expressed in the central nervous system (CNS) and participate in its normal and pathological functions. Among P2X receptors, the P2X7 receptor (P2rx7) has received considerable interest in both basic and clinical neuropsychiatric research because of its profound effects in animal CNS pathology and its potential involvement as a susceptibility gene in mood disorders. Although genetic findings were not always consistently replicated, several studies demonstrated that single nucleotide polymorphisms (SNPs) in the human P2X7 gene (P2RX7) show significant association with major depressive disorder and bipolar disorder. Animal studies revealed that the genetic knock-down or pharmacological antagonism leads to reduced depressive-like behavior, attenuated response in mania-model and alterations in stress reactivity. A potential mechanism of P2rx7 activation on mood related behavior is increased glutamate release, activation of extrasynaptic NMDA receptors and subsequent enduring changes in neuroplasticity. In addition, dysregulation of monoaminergic transmission and HPA axis reactivity could also contribute to the observed changes in behavior. Besides P2rx7, the inhibition of adenosine A1 and A 2A receptors also mediate antidepressant-like effects in animal experiments. In conclusion, despite contradictions between existing data, these findings point to the therapeutic potential of the purinergic signaling system in mood disorders.

AB - The purinergic signaling system consists of transporters, enzymes and receptors responsible for the synthesis, release, action and extracellular inactivation of adenosine 5'-triphosphate (ATP) and its extracellular breakdown product adenosine. The actions of ATP are mediated ionotropic P2X and metabotropic P2Y receptor subfamilies, whilst the actions of adenosine are mediated by P1 adenosine receptors. Purinergic signaling pathways are widely expressed in the central nervous system (CNS) and participate in its normal and pathological functions. Among P2X receptors, the P2X7 receptor (P2rx7) has received considerable interest in both basic and clinical neuropsychiatric research because of its profound effects in animal CNS pathology and its potential involvement as a susceptibility gene in mood disorders. Although genetic findings were not always consistently replicated, several studies demonstrated that single nucleotide polymorphisms (SNPs) in the human P2X7 gene (P2RX7) show significant association with major depressive disorder and bipolar disorder. Animal studies revealed that the genetic knock-down or pharmacological antagonism leads to reduced depressive-like behavior, attenuated response in mania-model and alterations in stress reactivity. A potential mechanism of P2rx7 activation on mood related behavior is increased glutamate release, activation of extrasynaptic NMDA receptors and subsequent enduring changes in neuroplasticity. In addition, dysregulation of monoaminergic transmission and HPA axis reactivity could also contribute to the observed changes in behavior. Besides P2rx7, the inhibition of adenosine A1 and A 2A receptors also mediate antidepressant-like effects in animal experiments. In conclusion, despite contradictions between existing data, these findings point to the therapeutic potential of the purinergic signaling system in mood disorders.

KW - Adenosine

KW - ATP

KW - Bipolar disorder

KW - Depressive disorder

KW - P2X7 receptor

KW - Purinergic receptors

UR - http://www.scopus.com/inward/record.url?scp=84874083128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874083128&partnerID=8YFLogxK

U2 - 10.5706/nph201212003

DO - 10.5706/nph201212003

M3 - Article

C2 - 23269209

AN - SCOPUS:84874083128

VL - 14

SP - 231

EP - 238

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -